Eupraxia Pharmaceuticals(EPRX)
$8.06+0.43 (+5.64%)
EPRX
Eupraxia Pharmaceuticals financials statements
$8.06
At close:+0.43 (+5.64%)
Eupraxia Pharmaceuticals (EPRX) Ratios
48 Followers
Eupraxia Pharmaceuticals Ratios
EPRX's free cash flow for Q2 2026 was C$-12.91M. For the 2026 fiscal year, EPRX's free cash flow was decreased by C$-169.28K and operating cash flow was C$-12.74M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 15.12 | 7.72 | 0.78 | 6.08 | 13.49 |
| Quick Ratio | 15.12 | 7.72 | 0.78 | 6.08 | 13.49 |
| Cash Ratio | 14.31 | 7.42 | 1.00 | 5.97 | 9.21 |
| Solvency Ratio | -6.85 | -5.40 | -1.46 | -1.59 | -1.96 |
| Operating Cash Flow Ratio | -5.17 | -6.72 | -1.09 | -4.53 | -6.46 |
| Short-Term Operating Cash Flow Coverage | -370.99 | -417.66 | -2.03 | -236.43 | -196.69 |
| Net Current Asset Value | C$ 79.25M | C$ 29.97M | C$ -5.74M | C$ 10.66M | C$ 18.93M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.39 | 0.41 | 0.30 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 4.72 | 0.82 | 0.47 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.83 | 0.45 | 0.32 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.48 | 0.31 |
| Financial Leverage Ratio | 1.05 | 1.05 | 12.06 | 2.01 | 1.53 |
| Debt Service Coverage Ratio | -496.55 | -23.79 | -2.43 | -13.83 | -15.04 |
| Interest Coverage Ratio | 0.00 | -28.15 | -23.36 | -14.25 | -16.10 |
| Debt to Market Cap | 0.00 | 0.00 | 0.11 | 0.17 | 0.27 |
| Interest Debt Per Share | 0.00 | 0.03 | 0.50 | 0.63 | 0.76 |
| Net Debt to EBITDA | 2.07 | 1.41 | 0.40 | 0.64 | 0.52 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 99.97% | 99.07% | 95.42% | 97.25% | 98.37% |
| EBT Per EBIT | 100.40% | 95.33% | 106.20% | 105.67% | 111.96% |
| Return on Assets (ROA) | -45.64% | -69.48% | -139.92% | -89.89% | -73.63% |
| Return on Equity (ROE) | -47.93% | -72.68% | -1687.19% | -180.93% | -112.77% |
| Return on Capital Employed (ROCE) | -48.66% | -84.34% | -3135.82% | -104.15% | -72.09% |
| Return on Invested Capital (ROIC) | -48.56% | -83.94% | -423.20% | -103.53% | -67.66% |
| Return on Tangible Assets | -45.64% | -69.48% | -139.92% | -89.89% | -73.63% |
| Earnings Yield | -9.52% | -15.87% | -28.84% | -33.04% | -65.88% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.73 | -0.88 | -1.16 | -0.97 | -1.03 |
| Free Cash Flow Per Share | -0.74 | -0.89 | -1.16 | -0.99 | -1.06 |
| Dividend Paid and CapEx Coverage Ratio | -48.48 | -287.78 | -380.45 | -60.89 | -33.92 |
| Capital Expenditure Coverage Ratio | -48.48 | -287.78 | -380.45 | -60.89 | -33.92 |
| Operating Cash Flow Coverage Ratio | -188.55 | -417.41 | -2.67 | -1.78 | -1.54 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -7.19% | -19.67% | -21.61% | -27.11% | -43.20% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.83 | -6.26 | -3.47 | -3.03 | -1.52 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 5.04 | 4.58 | 58.51 | 5.48 | 1.71 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -13.91 | -5.08 | -4.63 | -3.69 | -2.31 |
| Price-to-Operating Cash Flow Ratio | -14.19 | -5.10 | -4.64 | -3.75 | -2.38 |
| Price-to-Earnings Growth (PEG) Ratio | -0.21 | 0.16 | -0.11 | 0.12 | -0.00 |
| Enterprise Value Multiple | -8.54 | -5.12 | -3.06 | -2.54 | -1.07 |
| Enterprise Value | 332.08M | 120.00M | 114.61M | 56.20M | 23.50M |
| EV to EBITDA | -8.54 | -5.12 | -3.06 | -2.54 | -1.07 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -11.20 | -3.99 | -4.09 | -2.94 | -1.56 |
| EV to Operating Cash Flow | -11.43 | -4.00 | -4.11 | -2.99 | -1.60 |
| Tangible Book Value Per Share | 2.01 | 0.90 | 0.05 | 0.59 | 1.37 |
| Shareholders’ Equity Per Share | 2.05 | 0.98 | 0.09 | 0.67 | 1.43 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | 0.00 | -0.04 | 0.06 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.98 | -0.72 | -1.55 | -1.21 | -1.61 |
| Tax Burden | 1.00 | 0.99 | 0.95 | 0.97 | 0.98 |
| Interest Burden | 1.00 | 1.04 | 1.04 | 1.07 | 1.06 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.75 | 1.17 | 0.75 | 0.79 | 0.63 |
Currency in CAD
